Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
Recruiting · NCT05450965 · Registry updated 2025-12-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 2 | 2025-12-17 | NCT05450965 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cardiff Oncology | 5 |
| National Cancer Institute (NCI) | 3015 |
| University of Maryland, Baltimore | 198 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore | United States | 20 |
| UPMC Hillman Cancer Center | Pittsburgh | United States | 330 |